Payout • Polaryx Therapeutics
PLYX
Polaryx Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for lysosomal storage disorders (LSDs) and other rare, life-threatening diseases. The company's primary focus is on repurposing and optimizing existing compounds to address the unmet medical needs of patients with genetic disorders that affect the central nervous system and other vital organs. Polaryx's lead product candidate, PLX-101, is an oral small molecule being developed for the treatment of Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL), also known as CLN2 disease. PLX-101 works by activating the Peroxisome Proliferator-Activated Receptor alpha (PPARα) and the Transcription Factor EB (TFEB), which are critical regulators of lysosomal biogenesis and autophagy. By enhancing these pathways, the therapy aims to reduce the accumulation of toxic storage material in cells, potentially slowing or halting disease progression. In addition to CLN2, the company is exploring the application of its technology platform across other forms of Neuronal Ceroid Lipofuscinosis (NCL) and various lysosomal storage diseases. Polaryx leverages a strategy of utilizing well-characterized molecules to accelerate clinical development timelines and reduce safety risks. The company is led by a management team with extensive experience in drug development and rare disease research, aiming to provide accessible, non-invasive treatment options for pediatric and adult patients worldwide.
0
Dividend Per Share
The sum of declared dividends issued by a company for every ordinary share outstanding.
0%
Dividend Yield
Dividend Yield is a financial ratio that shows how much a company pays out in dividends each year relative to its share price in the last twelve months. In the absence of any capital gains, the dividend yield is the return on investment for a stock.
-4%
Buyback Yield
It is another way that companies have to remunerate their shareholders, being an alternative to dividends. Shows the % of repurchases per share made in the last 12 months in relation to the share price.
-4%
Total Yield
Sum of Dividend Yield and BuyBack Yield to show the total return that the shareholder received in the last 12 months in relation to the share price.
0%
Payout
The dividend payout ratio is the ratio of the total amount of dividends paid out to shareholders relative to the net income of the company. It is the percentage of earnings paid to shareholders via dividends.
-102,2M
Retained Earnings
Retained earnings (RE) are the amount of net income left over for the business after it has paid out dividends to its shareholders and are an important variable for assessing a company's financial health because it shows the net income that a company has saved over time, and therefore has the ability to reinvest in the business or distribute to shareholders.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!